Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic, which introduced a wide variety of challenges and opportunities to the clinical development industry. Almost 27,000 clinical trials were initiated in 2021 across the world. Nearly half of these trials (12,900) had locations in APAC, followed by Europe (5,000) and the US (4,900). This represented growth of 5.3% per annum globally since 2017. While growth in clinical trials was seen universally, growth rates between regions were highly variable. In the US and RoW, growth was less than 2%, while EU growth was just under 3%. Growth in APAC, however, was almost 10%, contributing massively to the global scene.